regression analysis was used to identify other risk factors for implant failure.
Results: Patients with failed arthroplasty had significantly higher blood cobalt and chromium ion levels than did patients with non-failed arthroplasty (p < 0.01). Blood cobalt ion levels were disproportionately raised in patients with failed total hip arthroplasty (8.2 μg/L) compared with patients with failed hip resurfacing (2.5 μg/L) (p = 0.018). Blood chromium ion levels were not significantly different in patients with failed total hip arthroplasty and failed hip resurfacing (p = 0.058). The maximum value of either metal ion had good discriminant ability to predict implant failure (area under the curve, 0.76). A 7-μg/L cutoff had a positive predictive value of 0.75 (95% confidence interval, 0.66 to 0.82) and a negative predictive value of 0.82 (95% confidence interval, 0.78 to 0.86). In patients managed with total hip arthroplasty, for each increase of 1 μg/L there was a 23% (p < 0.001) increase in the odds of them being in the failed group. For patients managed with hip resurfacing, the increase in odds was 5% (p < 0.001).
Conclusions:
Raised levels of blood metal ions were associated with failed metal-on-metal hip resurfacings and total hip arthroplasties. A threshold level of 7 μg/L had inadequate sensitivity to be used in isolation as a screening test for implant failure, but it provided nearly optimal misclassification rates. No level had a perfect positive predictive value, and so we discourage surgeons from performing revision surgery based on blood metal ion levels alone. Levels of cobalt ions were raised out of proportion to levels of chromium ions in failed total hip arthroplasty and may reflect a different mechanism for metal ion generation.
Level of Evidence: Therapeutic Level III. See
Instructions for Authors for a complete description of levels of evidence.
There have been recent high-profile recalls of breast and orthopaedic prostheses, prompting interest in postmarket surveillance. The past decade has seen a surge in the use of metal-on-metal hip implants, as they appeared to be the optimal low-wearing and highperformance devices for younger, more active patients .
In 2008, approximately 35% of all hip replacements in However, in subsequent years there has been a decline in their use amid concerns of unacceptable early failure rates and adverse responses to metal debris .
In April 2010, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) published a medical device alert to guide the surveillance of all types of metal-on-metal hip arthroplasty . An "action level" of seven parts per billion (μg/L) for cobalt or chromium was suggested to select patients for more frequent surveillance and further testing (such as cross-sectional imaging). In the unexposed population (without metal-on-metal prostheses), the upper limit of the reference range for both cobalt and chromium ion levels is 0.5 μg/L . The authors of small studies have reported average whole blood levels of 1 to 2 μg/L for patients with wellfunctioning metal-on-metal hip implants and higher levels in patients with failed metal-on-metal hip arthroplasties . The MHRA action level provided a specificity of 89% and a sensitivity of 52% for detecting a preoperative, unexplained failed metal-on-metal hip resurfacing , but to our knowledge no authors have reported diagnostic test characteristics of blood metal ion levels following metal-on-metal total hip arthroplasties. Further, the results in recent studies comparing metal ion levels following hip resurfacing with those following large-diameter total hip arthroplasty are conflicting (see Appendix)
.
We recognize from our own practice and the existing literature that the decision to revise a metal-on-metal hip is not always straightforward. For instance, hip pain may be due to problems in other anatomical locations and consequently hip function scores do not quantify hip function alone. Tests for blood metal ion levels are now routinely available in many countries and at modest cost. The aim of this study was to determine the value of whole blood metal ion levels in predicting failure for both hip resurfacing and large-diameter total hip implants.
Study Design
We performed a prospective study involving 597
consecutive patients with current-generation, unilateral We included all patients who had given informed consent and who had unilateral, current-generation, large-diameter (head size >36 mm) metal-on-metal hip arthroplasty; whole blood metal ion levels that were measured more than twelve months following the primary surgery; and hip function recorded with use of the Oxford Hip Score (Fig. 1) . Thirty-nine cases scored only with the Harris hip score were excluded. 
Exclusion Criteria
Patients who underwent revision arthroplasty for a microbiologically confirmed infection and/or a periprosthetic fracture were excluded.
Definitions
We defined implant failures (n = 173) as prostheses that subsequently underwent revision, those for which a revision was planned, and those associated with a poor
Oxford Hip Score (<31 of 48). We defined non-failed implants (n = 424) as those in patients with at least moderate hip function (Oxford Hip Score, ≥31 of 48). is the maximum value of either whole blood cobalt or chromium ions.
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Analysis of Cobalt and Chromium Ion Levels
Blood was sampled from the antecubital vein with use 
Power Analysis
We based our power calculations on the aim of detecting a significant difference in sensitivity between the cutoff at about 5 and 7 μg/L. Areas under the receiver operating characteristic curves were compared with use of chi-square tests to identify differences in discriminant power between metal ion thresholds. A multiple logistic regression model was fitted to measure the effects of cobalt, chromium, or the 
Source of Funding
There was no external funding source.
LL RESULTS
Five hundred and ninety-seven patients met our entry criteria ( Fig. 1 and Table I ).
TABLE I
Demographics of the Patients Included in the Study
Metal Ion Levels
The median whole blood metal ion level in patients with non-failed hip implants was 1.6 μg/L for cobalt and 1.6 μg/L for chromium (1.9 μg/L for Max [Co, Cr] Cr) values were all significantly higher than for nonfailed arthroplasties (all p < 0.01) ( Table II) . 
there was no difference for chromium (p = 0.41), and cobalt and Max (Co, Cr) values were significantly higher for total hip arthroplasties (p < 0.0001 for both).
Diagnostic Test Characteristics and Receiver
Operating Characteristic Curves
Diagnostic test characteristics were similar for cobalt and Max (Co, Cr), while chromium tended to yield less effective discrimination, as shown in a plot allowing comparison of cobalt with chromium for selected cutoffs above and below the recommended cutoff of 7 μg/L (Fig. 2) Receiver operating characteristic (ROC) curve showing the abilities of cobalt (Co) and chromium (Cr) levels to discriminate failed from non-failed metal-on-metal hip implants.
TABLE III
Positive and Negative Predictive Values for the Cutoff of Seven Micrograms per Liter of Cobalt
Logistic Regression Analysis
The significant predictors for hip failure were Max (Co, Cr) and the interaction between metal ion and implant type (p < 0.001). For patients managed with total hip arthroplasty, for a unit increase in metal ions, there was a 23% increase in the odds of being in the failed group.
However, there was only a 5% increase in the odds for patients managed with hip resurfacing. This interaction between Max (Co, Cr) levels and implant type was virtually the same as the interaction between cobalt alone and implant type (odds ratio [OR] = 1.23 for total hip arthroplasty and 1.05 for hip resurfacing; p < 0.001).
For chromium alone, the interaction with implant type was significant but implant type was also significant (OR = 0.44); that is, the odds of a failed hip in patients managed with total hip arthroplasty are 2. 
Stratified Analysis by Implant Type
Hip resurfacings and total hip arthroplasties had different effects on blood metal ion levels. The prevalence of hip failure was 0.16 in patients managed with hip resurfacing and 0.40 in those managed with total hip arthroplasty. The specificity and sensitivity of both cobalt and Max (Co, Cr) at 7 μg/L for predicting hip failure were 87% (95% CI, 81% to 91%) and 55% (95% CI, 46% to 64%) in total hip arthroplasty, and they were 98% (95% CI, 95% to 99%) and 39% (95% CI, 25% to 55%) in hip resurfacing. The specificity and sensitivity for chromium at 7 μg/L were 99% (95% CI, 96% to 100%) and 26% (95% CI, 19% to 35%) for total hip arthroplasty, and they were 98% (95% CI, 95% to 99%) and 33% (95% CI, 20% to 48%) for hip resurfacing.
Thus, for hip resurfacing it appears that the performance of the diagnostic test with Max (Co, Cr) (which at 7 μg/L is the same as that for cobalt alone) is very similar to performance of the diagnostic test with chromium alone. However, for total hip arthroplasty, the performance of the diagnostic test differs even more markedly for chromium and cobalt than in the analysis combining total hip arthroplasty and hip resurfacing implants. This reflects a different distribution and role in the prediction of hip failure for cobalt and chromium in total hip arthroplasty and hip resurfacing, with cobalt and chromium having a more similar distribution in hip resurfacing than in total hip arthroplasty. Although the misclassification rates are nearly optimal at 7 μg/L for Max (Co, Cr) for both total hip arthroplasty and hip resurfacing (26% and 12%), a lower threshold for hip resurfacing would allow a better balance between sensitivity and specificity.
LL DISCUSSION
The results of this study have confirmed that blood metal ions are significantly higher in patients with failed compared with non-failed metal-on-metal hip arthroplasties. We believe that this is the first study to identify this separately for both hip resurfacing and total hip arthroplasty. Blood metal ion measurement is now so commonly performed that the recruitment of large they were in total hip arthroplasty. Cobalt ion levels were raised out of proportion to chromium ion levels in failed total hip arthroplasty, which may reflect a different mechanism for metal ion generation. However, the reduced cohort size in the implant type-stratified analyses might hinder the generalizability of the performance of the ion-level diagnostic tests beyond this cohort. More generally, the smaller size of the subgroup analyses suggests that, for the purpose of predicting hip failure, a model-based procedure derived on the entire data set should be used. This would simultaneously take into account the multivariate data available on the patients to maximize the area under the curve, instead of using the metal ion dimension only (which nonetheless retains its appeal for its simplicity to aid in decision-making).
Strengths and Limitations of the Study
To our knowledge, this is the first prospective, single- whether blood metal ion levels have similar diagnostic test characteristics in patients with metal-on-metal hip arthroplasty designs other than those analyzed in the current study.
We recommend that future work focus on determining whether blood metal ion levels are able to predict softtissue damage, because such a prediction would trigger a decision to revise. To achieve this prediction, there needs to be a consensus on the interpretation of metal artifact reduction sequence MRI, such as on the clinical meaning of a cystic pseudotumor, which may be found in patients with well-functioning metal-on-metal implants.
Revision surgery, or intention to revise (if surgery is pending), is the most important determinant in the fate of these devices. Patient-reported hip-function scores, which are variable and have inherent limitations, were not used as the sole assignment tool in our allocation of patients. Importantly, our decision to revise was not based on blood metal ion measurements.
Comparison with Other Studies
There is no report that we are aware of on the specificity and sensitivity of whole blood metal ion levels 
LL CONCLUSIONS AND POLICY IMPLICATIONS
Raised blood metal ion levels were associated with failed metal-on-metal hip resurfacing and total hip arthroplasties. A threshold level of 7 μg/L had inadequate sensitivity to be used in isolation as a screening test for implant failure, but it provided nearly optimal misclassification rates. No level had a perfect positive predictive value. Therefore, we discourage surgeons from performing revision surgery based on blood metal ion levels alone. Cobalt ion levels were raised out of proportion to chromium ion levels in failed total hip arthroplasty, which may reflect a different mechanism for metal ion generation.
LL APPENDIX
A table showing a summary of studies comparing blood metal ion levels in patients with hip resurfacing and large-diameter metal-on-metal total hip implants as well 
